08 Dec 2025
9m
ASH 2025: Cullinan Therapeutics CEO Nadim Ahmed highlights the company's FLT3xCD3 bispecific T-cell engager data at ASH in AML and MDS
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.